Dr. Petrylak highlights findings from TROPHY-U-01 trial in metastatic urothelial cancer
"[This is] a group of patients that there are few treatments available for, and we're excited about the data," says Daniel P. Petrylak, MD.
In this video, Daniel P. Petrylak, MD, discusses the background and findings from a primary analysis of cohort 2 of the TROPHY-U-01 trial, which analyzed sacituzumab govitecan in platinum-ineligible patients with metastatic urothelial cancer. The findings were presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco, California. Petrylak is a professor of medicine and urology at the Yale School of Medicine in New Haven, Connecticut.
Video Transcript:
Sacituzimab govitecan is an [antibody-drug conjugate] (ADC) that recognizes Trop-2 which is expressed in a number of different tumors. It also delivers SN-38, which is a topoisomerase inhibitor. It's got about 38 times more activity. The TROPHY trial has 6 different cohorts. This is the second cohort which was evaluating sacituzimab in those patients who were ineligible to receive platinum.
What we found was that there was a 32% response rate in these patients. In those patients who had not had prior chemotherapy, the response rate was 50%. This is looking active, in this group of patients. The characteristics with patients included that they had to have received prior immune therapy, and they could have received prior chemotherapy in the neoadjuvant setting. It's a group of patients that there are few treatments available for, and we're excited about the data.
This transcription has been edited for clarity.
Personalized therapeutic approaches in ccRCC remain challenging
April 15th 2024"As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies or not," says David A. Braun, MD, PhD.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
Subcutaneous nivolumab meets coprimary pharmacokinetic end points for ccRCC
January 30th 2024Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).
